Abstract
Introduction: Most drugs cannot be delivered in isolation and therefore require excipients to ensure suitability of the dosage form. Excipients can cause unwanted effects; however the quantity of excipients in products is not commonly accounted for during prescribing. Paediatric patients are particularly vulnerable to the potential toxic effects of excipients, especially those in intensive care settings. The aim of this study was to identify and quantify the excipients included in the medications administered to a selection of patients from the Paediatric Intensive Care Unit (PICU) at Birmingham Children’s Hospital.
Materials & Methods Design: Data were collected from five randomly selected patients. Manufacturers were contacted to ascertain excipient quantities present. Setting: Paediatric Intensive Care Unit (PICU), Birmingham Children’s Hospital, UK.
Main outcome measures: Identity and quantity of excipients administered.
Results: In total, twenty-seven manufacturers were contacted, and two-thirds (67%, n = 18/27) responded to the information request. Overall (excluding intravenous fluids), the patients were taking 49 medicines; however, it was only possible to find out the details for all of the excipients present for 22% (n = 11/49) of products, with details for selected excipients provided for 31% (n = 15/49) of products. Although in-depth analysis of the excipients could not be carried out due to the limited response from the manufacturers, it was still evident that some patients were receiving potentially toxic excipient doses. For example, one multi-syndrome infant was receiving five times the WHO recommended maximum daily amount of propylene glycol a day, from one medicinal product.
Discussions, Conclusion: The lack of readily available information from manufacturers on excipients and their quantities is worrying. This small study has indicated that some paediatric patients receive potentially toxic levels of selected excipients. For example, excessive propylene glycol can cause ototoxicity, nephrotoxicity, lactic acidosis and seizure in children. Therefore, it is vital that excipients are monitored in PICU patients and information on excipient quantities should be readily available for practitioners to refer to when required.
Disclosure of Interest: None Declared.
Materials & Methods Design: Data were collected from five randomly selected patients. Manufacturers were contacted to ascertain excipient quantities present. Setting: Paediatric Intensive Care Unit (PICU), Birmingham Children’s Hospital, UK.
Main outcome measures: Identity and quantity of excipients administered.
Results: In total, twenty-seven manufacturers were contacted, and two-thirds (67%, n = 18/27) responded to the information request. Overall (excluding intravenous fluids), the patients were taking 49 medicines; however, it was only possible to find out the details for all of the excipients present for 22% (n = 11/49) of products, with details for selected excipients provided for 31% (n = 15/49) of products. Although in-depth analysis of the excipients could not be carried out due to the limited response from the manufacturers, it was still evident that some patients were receiving potentially toxic excipient doses. For example, one multi-syndrome infant was receiving five times the WHO recommended maximum daily amount of propylene glycol a day, from one medicinal product.
Discussions, Conclusion: The lack of readily available information from manufacturers on excipients and their quantities is worrying. This small study has indicated that some paediatric patients receive potentially toxic levels of selected excipients. For example, excessive propylene glycol can cause ototoxicity, nephrotoxicity, lactic acidosis and seizure in children. Therefore, it is vital that excipients are monitored in PICU patients and information on excipient quantities should be readily available for practitioners to refer to when required.
Disclosure of Interest: None Declared.
| Original language | English |
|---|---|
| Article number | IDMD-029 |
| Pages (from-to) | 167 |
| Number of pages | 1 |
| Journal | International Journal of Clinical Pharmacy |
| Volume | 34 |
| Issue number | 1 |
| Early online date | 8 Jan 2012 |
| Publication status | Published - Feb 2012 |
| Event | ESCP 40th International Symposium on Clinical Pharmacy: Clinical pharmacy: connecting care and outcomes - Dublin, Ireland Duration: 19 Oct 2011 → 21 Oct 2011 |
Bibliographical note
AbstractsFingerprint
Dive into the research topics of 'A review of excipient levels in paediatric intensive care unit (PICU) patients'. Together they form a unique fingerprint.Research output
- 5 Conference abstract
-
Analysis of anticoagulation therapy for critical care haemofiltration patients
Langley, C. A., Goray, G. K. & Graham-Clarke, E. M., Feb 2012, In: International Journal of Clinical Pharmacy. 34, 1, p. 208 1 p., PC-099.Research output: Contribution to journal › Conference abstract › peer-review
-
A review of tobramycin levels in paediatric cystic fibrosis patients
Langley, C. A., Nock, M. C., Paskin, L. E. & Desai, M., Feb 2012, In: International Journal of Clinical Pharmacy. 34, 1, p. 250 1 p., PT-042.Research output: Contribution to journal › Conference abstract › peer-review
-
PEARs 1 —Undergraduate clinical placement education in Irish pharmacy schools
Langley, C. A. & Wilson, K. A., Feb 2012, In: International Journal of Clinical Pharmacy. 34, 1, p. 156-157 2 p., ECP-022.Research output: Contribution to journal › Conference abstract › peer-review
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver